> News
News2016-12-11T21:08:15+00:00

News

Viglya wishes to establish transparent and open communication with its stakeholders. This section offers new and updated information regarding the company and the life science sector.

FDA approves a new generic valsartan

Today, the U.S. Food and Drug Administration approved a new generic of Diovan (valsartan). Valsartan is an angiotensin II receptor blocker (ARB) that treats high blood pressure and heart failure. The FDA prioritized the review [...]

14.03.2019|
Find out why Viglya is your strategic partner in drug development.Read more